SOURCE CONTENT
来源摘要(中文)
The Federal Trade Commission filed an amicus brief in an antitrust case alleging that drug manufacturer Amgen illegally acquired exclusive rights to patent applications that it shaped to cover Enbrel—a drug used to treat rheumatoid arthritis and other inflammatory conditions—allowing Amgen to extend its monopoly over the biologic drug. View Press Release
BUSINESS NOTE
经营分析
涉及法律或知识产权风险,选品与投放前应复核权利状态。 建议先区分起诉、禁令、判决或和解阶段,再比对涉案商标、专利、图片与自身商品;涉及正式投诉或资金冻结时,应尽快交由目标市场专业人员处理。
SOURCES
原始信息来源
查看原始页面可核对标题、正文、发布日期、适用范围与后续修订。
- 官方jhenderson2来源发布日期:2026/08/21 20:00查看原始来源 ↗